View Entire Prescribing Information and facts OPDIVO® (nivolumab) is indicated to the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more strains of systemic therapy that includes autologous HSCT.